Sono-tek Stock Earnings Reports

Sono‑Tek reported modest revenue growth in Q2 and the first half of fiscal 2026 with record first‑half revenue of $10.3M and net income of $917K (up ~36% year‑over‑year). Q2 revenue was $5.16M, marking the sixth consecutive quarter above $5M. The company ended the period with a strong, near‑record backlog of $11.2M, cash and marketable securities of $10.6M and no debt. Management highlighted strong momentum in the medical device market (Q2 medical sales +150% YoY) driven by balloon catheter and stent applications, and noted several large orders recently announced (including an order >$5.0M and another >$2.8M to medical customers). Sono‑Tek is executing a strategic shift toward larger, higher‑ASP, more complex production systems and forward‑deployed engineering (application engineering embedded with customers) to shorten sales cycles, increase win rates and expand margins over the next 1–2 years. Clean energy demand is expected to be softer this year due to policy/tariff uncertainty, which management says will be partially offset by medical market strength and diversification. Guidance was raised to reflect modest revenue growth for the full fiscal year, but timing of large system builds means much of the big new medical orders will ship in FY2027, so near‑term results will be somewhat timing‑dependent. Key investor takeaways: solid profitability improvement and margins (gross margin ~50–51%; operating margin improved), strong balance sheet and backlog, accelerating medical segment traction, higher ASP product mix driving improved profitability, and execution/timing risk around large systems and exposure to macro/policy factors (tariffs, clean energy policy).